PPARG and hepatocellular carcinoma: PPARγ targets cyclin D1 via the inhibitors ofcyclin-dependent kinases (Cdk), p18, p21, and p27, causing a decline in Rb phosphorylation[1] and arresting cells in G1phase: PPARγ acts via p21 and p27 in pancreaticcancer and via p18 in hepatoma (see Figure 3(a)).